Profitability Ratios
| Ratio |
Value |
| GP Margin |
59.9% |
| EBIT Margin |
-31.5% |
| EBITDA Margin |
-29.5% |
| Operating Margin |
-29.9% |
| Pretax Margin |
-31.9% |
| Cont. Ops Margin |
-32.5% |
| Net Margin |
-32.5% |
| Bottom Line Margin |
-32.5% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.32 |
| Quick Ratio |
1.48 |
| Solvency Ratio |
-0.303 |
| Cash Ratio |
0.73 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.01 |
| Forward PEG |
0.01 |
| Price/Book |
1.98 |
| Price/Sales |
1.03 |
| Price/FCF |
-7.33 |
| Price/Op Cash Flow |
-10.98 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.3103 |
| Debt/Equity |
0.9114 |
| Debt/Capital |
0.4768 |
| Long-Term Debt/Capital |
0.4209 |
| Financial Leverage |
2.94 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.16 |
| Operating Cash Flow Ratio |
-0.188 |
| Operating Cash Flow/Sales |
-9.3% |
| Free Cash Flow/Operating Cash Flow |
149.6% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-31.50 |
| Interest Coverage |
-67.5955 |
| Short-Term Operating Cash Flow Coverage |
-18.35 |
| Operating Cash Flow Coverage |
-0.20 |
| Capital Expenditure Coverage |
-2.02 |
| Dividend + Capital Expenditure Coverage |
-2.02 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
20.98 |
| EPS |
-6.808 |
| Debt/Share |
10.0129 |
| Cash/Share |
8.97 |
| Book Value/Share |
10.88 |
| Tangible BV/Share |
10.61 |
| Equity/Share |
10.88 |
| Operating Cash Flow/Share |
-1.961 |
| Capital Expenditure/Share |
0.973 |
| FCF/Share |
-2.934 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.016 |
| Earnings Before Tax/EBIT |
1.068 |
| Price/Fair Value |
1.98 |
| Debt/Market Cap |
0.3726 |
| Effective Tax Rate |
-1.6% |
| Enterprise Value Multiple |
-3.85 |
SRPT - Sarepta Therapeutics, Inc.